Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
ACRV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $10.00
Previous CloseN/A
Volume1.72K
Average Volume (3M)231.47K
Market Cap
$42.15M
Enterprise Value-$88.39M
Total Cash (Recent Filing)$137.42M
Total Debt (Recent Filing)$3.26M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Nov 06, 2025EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding31,455,645
10 Day Avg. Volume187,524
30 Day Avg. Volume231,467
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-2.10
Enterprise Value/Revenue-104.23
Enterprise Value/Gross Profit72.81
Enterprise Value/Ebitda0.97
Forecast
1Y Price Target
$11.75Price Target Upside776.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressNo dose-limiting toxicities have been identified in the Phase 1 study for ACR-2316, and early signals supporting efficacy are emerging.
Drug DevelopmentThe expansion of P2 to include a biomarker agnostic combo cohort is noted as a positive development.
Financial StabilityManagement anticipates a cash runway extending into the second quarter of 2027, indicating financial stability.
Bears Say
CompetitionExpectations for ACR-368 are falling behind competitors like Eisai's E7386.
Financial ConcernsCash/share is projected to drop significantly by mid-2026 if no capital raise occurs.
Stock PressurePressure on the stock has been observed due to the lower than expected efficacy of ACR-368 in the BM+ endometrial cancer setting.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.05 and its highest was $10.00 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $42.15M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 64 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Aug 13, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.568 by $0.018.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.59.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,455,645 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.568. Following the earnings report the stock price went up 6.107%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
Acrivon Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (776.87% Upside)
$11.75 (776.87% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.57%
12-Months-Change
Fundamentals
Return on Equity
-47.87%
Trailing 12-Months
Asset Growth
-31.23%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$11.75
▲(776.87% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Bluebird Bio
―
Avalo Therapeutics
―
Sutro Biopharma
―
Fractyl Health, Inc.
―